NASDAQ:NMAD

Lixte Biotechnology Q3 2026 Earnings Results & Report

Lixte Biotechnology logo
$2.63 -0.22 (-7.72%)
As of 11:01 AM Eastern

Lixte Biotechnology reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.74, while revenue was $472 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Lixte Biotechnology EPS Results

Actual EPS
-$0.74
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lixte Biotechnology Revenue Results

Actual Revenue
$472 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Lixte Biotechnology Q3 2026 Earnings FAQ

Lixte Biotechnology (NASDAQ:NMAD) reported earnings of -$0.74 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

Lixte Biotechnology reported revenue of $472 thousand for Q3 2026.

Lixte Biotechnology Earnings Headlines

Lixte Biotechnology (NASDAQ:NMAD) Shares Up 7.1% - Time to Buy?
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Lixte Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lixte Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lixte Biotechnology and other key companies, straight to your email.

About Lixte Biotechnology

Lixte Biotechnology (NASDAQ:NMAD) Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response.

The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy. LB-100 is investigational and has not been approved as a treatment.

View Lixte Biotechnology Profile